Journal Article

Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?

Ivica Avbersek-Luznik, Breda Pečovnik Balon, Igor Rus and Janja Marc

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 20, issue 3, pages 566-570
Published in print March 2005 | ISSN: 0931-0509
Published online January 2005 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/gfh672
Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?

Show Summary Details

Preview

Background. The receptor activator of nuclear factor κB ligand (RANKL), produced by osteoblasts/stromal cells, is a member of the RANK/RANKL/OPG system, which regulates bone resorption by osteoclasts. Since RANKL and osteoprotegerin (OPG) production in bone is influenced by parathyroid hormone (PTH), we measured serum RANKL and OPG concentrations in haemodialysis (HD) patients, who commonly hypersecrete PTH. We aimed to determine if clinically demonstrated PTH-enhanced bone resorption is a consequence of increased RANKL synthesis.

Methods. RANKL, OPG, osteocalcin, intact PTH, bone-specific alkaline phosphatase, tartrate-resistant acid phosphatase 5b and β-CrossLaps (CTx) were measured in blood samples from 80 HD patients and 50 age-matched controls. HD patients were stratified to tertiles according to their serum PTH levels: 29.3–103.0, 109.7–263.0 and 262.0–1700.0 pg/ml in the first, second and third tertiles, respectively.

Results. Mean serum RANKL levels were 1.6 times higher in HD patients than in age-matched controls (1.36±0.39 vs 0.83±0.70 pmol/l; P<0.001). All the measured bone markers significantly differed between patients and controls (P<0.001). Spearman's tests of correlation showed a statistically significant association of RANKL with PTH, osteocalcin and CTx (r = 0.322, P = 0.004; r = 0.231, P = 0.039; and r = 0.230, P = 0.040, respectively). Mean serum RANKL levels were significantly different between PTH tertiles (P = 0.003), but serum OPG levels were not (P = 0.144). The highest RANKL levels were measured in the upper PTH tertile (1.54±0.39 pmol/l) and were significantly higher than in the middle or lower tertiles (1.27±0.42 and 1.23±0.26 pmol/l, respectively; P = 0.003). Both of the measured bone-resorption markers, tartarate-resistant acid phosphatase 5b and CTx, as well as both bone formation markers, osteocalcin and bone-specific alkaline phosphatase were also significantly higher in the upper tertile, indicating that whole-bone remodelling is activated at high PTH and RANKL levels.

Conclusions. Serum RANKL levels were significantly higher in HD patients than in healthy age-matched controls. Moreover, RANKL levels were significantly higher in the upper PTH tertile, indicating enhanced RANKL synthesis in a PTH-dependent fashion. Thus, our clinical findings clearly support published in vitro studies that demonstrated a stimulating effect of PTH on RANKL synthesis. Therefore, the hypothesis that PTH increases bone resorption in HD patients through RANKL appears valid.

Keywords: bone biochemical markers; bone turnover; osteoprotegerin ligand; parathyroid hormone; renal osteodystrophy; RANKL

Journal Article.  2520 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.